415 related articles for article (PubMed ID: 32259446)
1. Molecule Property Analyses of Active Compounds for
Makarov V; Salina E; Reynolds RC; Kyaw Zin PP; Ekins S
J Med Chem; 2020 Sep; 63(17):8917-8955. PubMed ID: 32259446
[TBL] [Abstract][Full Text] [Related]
2. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Stover CK; Warrener P; VanDevanter DR; Sherman DR; Arain TM; Langhorne MH; Anderson SW; Towell JA; Yuan Y; McMurray DN; Kreiswirth BN; Barry CE; Baker WR
Nature; 2000 Jun; 405(6789):962-6. PubMed ID: 10879539
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
Showalter HD
Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
5. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.
Fang C; Lee KK; Nietupski R; Bates RH; Fernandez-Menendez R; Lopez-Roman EM; Guijarro-Lopez L; Yin Y; Peng Z; Gomez JE; Fisher S; Barros-Aguirre D; Hubbard BK; Serrano-Wu MH; Hung DT
Bioorg Med Chem Lett; 2018 Dec; 28(22):3529-3533. PubMed ID: 30316633
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. New potential drug leads against MDR-MTB: A short review.
Gatadi S; Nanduri S
Bioorg Chem; 2020 Jan; 95():103534. PubMed ID: 31884135
[TBL] [Abstract][Full Text] [Related]
9. Molecular Players in Tuberculosis Drug Development: Another Break in the Cell Wall.
Squeglia F; Romano M; Ruggiero A; Berisio R
Curr Med Chem; 2017 Nov; 24(36):3954-3969. PubMed ID: 28183257
[TBL] [Abstract][Full Text] [Related]
10.
Sawicki R; Ginalska G
Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
[TBL] [Abstract][Full Text] [Related]
11. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
12. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase.
Van Calenbergh S; Pochet S; Munier-Lehmann H
Curr Top Med Chem; 2012; 12(7):694-705. PubMed ID: 22283813
[TBL] [Abstract][Full Text] [Related]
13. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
14. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents.
Song L; Risseeuw MDP; Froeyen M; Karalic I; Goeman J; Cappoen D; Van der Eycken J; Cos P; Munier-Lehmann H; Van Calenbergh S
Bioorg Med Chem; 2016 Nov; 24(21):5172-5182. PubMed ID: 27614917
[TBL] [Abstract][Full Text] [Related]
15. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
[TBL] [Abstract][Full Text] [Related]
16. Microbiology. An antibiotic mimics immunity.
Nathan C
Science; 2008 Nov; 322(5906):1337-8. PubMed ID: 19039126
[No Abstract] [Full Text] [Related]
17. Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.
San Jose G; Jackson ER; Haymond A; Johny C; Edwards RL; Wang X; Brothers RC; Edelstein EK; Odom AR; Boshoff HI; Couch RD; Dowd CS
ACS Infect Dis; 2016 Dec; 2(12):923-935. PubMed ID: 27676224
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents.
Jian Y; Hulpia F; Risseeuw MDP; Forbes HE; Munier-Lehmann H; Caljon G; Boshoff HIM; Van Calenbergh S
Eur J Med Chem; 2020 Sep; 201():112450. PubMed ID: 32623208
[TBL] [Abstract][Full Text] [Related]
19. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
[TBL] [Abstract][Full Text] [Related]
20. Maximizing bactericidal activity with combinations of bioreduced drugs.
Goldman RC
Future Med Chem; 2010 Aug; 2(8):1253-71. PubMed ID: 21426017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
